Tissue-Specific Differential Flux Analysis Reveals Metabolic Insights Into Pancreatic β-Cell Dysfunction in Type 2...

Area of Science:

• Metabolic Engineering
• Computational Biology
• Endocrinology

Background:

• Type 2 diabetes (T2D) is a metabolic disorder marked by impaired glucose homeostasis due to pancreatic beta-cell dysfunction.
• Understanding beta-cell metabolic mechanisms is crucial for developing new T2D therapies.

Purpose of the Study:

• To construct genome-scale metabolic models for healthy and T2D pancreatic beta-cells.
• To identify metabolic alterations contributing to T2D pathogenesis and beta-cell failure.
• To discover potential therapeutic targets and drug candidates for T2D.

Main Methods:

• Reconstruction of context-specific genome-scale metabolic models using transcriptomics data.
• Analysis of metabolic flux profiles in healthy versus T2D beta-cells.
• Identification of biomarker genes and drug repurposing analysis.

Main Results:

• Significant metabolic flux profile shifts were observed in T2D beta-cells.
• Disruptions in glucose metabolism, insulin biosynthesis, and amino sugar/acid metabolism were identified.
• Reduced ubiquinone synthesis and increased fatty acid oxidation contribute to T2D beta-cell dysfunction.
• Biomarker genes for beta-cell failure were identified, leading to 23 potential drug targets, including 7 known T2D treatments.

Conclusions:

• Metabolic dysregulation in beta-cells is central to T2D pathogenesis.
• Identified metabolic pathways and biomarker genes offer novel therapeutic avenues.
• Drug repurposing analysis identified 341 FDA-approved drug candidates for T2D treatment.